The prevalence of chronic illnesses such as cancer, cardiovascular disease, and autoimmune ailments has increased dramatically, necessitating the urgent development of effective therapies. Cell treatments have emerged as a viable answer by providing focused and personalized techniques, especially for patients who have not responded to traditional therapy. The increased patient population and desire for more effective therapies for certain diseases are driving the worldwide cell therapy technologies market. Cell therapy development and commercialization have been aided by supportive regulatory regimes. Furthermore, a growth in cell therapy knowledge and acceptability among healthcare professionals and patients is boosting worldwide cell therapy technologies market demand.
Cell therapy advancements for the treatment of numerous chronic illnesses present profitable potential for market participants. Companies are working to increase the efficacy and safety of cell treatments in order to give better disease management results for patients.
The cell therapy technologies market is a medical treatment sector that involves the use of live cells to heal or enhance the function of damaged or diseased tissues and organs. Within the larger field of regenerative medicine, it is a fast expanding and promising area of study and development.
Cell therapy technologies have the potential to transform the treatment of a wide range of illnesses, including cancer, cardiovascular disease, neurological disorders, and autoimmune diseases. In the cell therapy technologies market, product development is characterized by continuing research and clinical studies to assess the safety and efficacy of various cell-based medicines.
Cell-based immunotherapies, gene treatments, tissue engineering, and ex vivo cell multiplication methods are among the options being investigated by scientists and corporations. CAR-T cell treatments for cancer therapy have made significant advances, with immune cells genetically modified to recognize and target cancer cells.
Stem cell treatments are being researched for problems such as spinal cord injury, heart disease, and neurodegenerative disorders. Ongoing research and product development initiatives aim to broaden the spectrum of available cell treatments while improving their safety, effectiveness, and accessibility.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Cell Therapy Technologies Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Cell Therapy Technologies Market , as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered.
The segmentation coverage of the study is provided below.
Cell Therapy Technologies Market based on Therapy Type:
- Allogeneic Therapies
- Stem Cell Therapies
- Hematopoietic Stem Cell Therapies
- Mesenchymal Stem Cell Therapies
- Non-Stem Cell Therapies
- Keratinocytes & Fibroblast-based Therapies
- Others
- Autologous Therapies
- Stem Cell Therapies
- BM, Blood, & Umbilical Cord-derived Stem Cells
- Adipose derived cells
- Others
- Non-Stem Cell Therapies
- T-Cell Therapies
- CAR T Cell Therapy
- T Cell Receptor (TCR)-based
Cell Therapy Technologies Market based on Therapeutic Area:
- Oncology
- Cardiovascular Disease (CVD)
- Musculoskeletal Disorders
- Dermatology
- Others
Cell Therapy Technologies Market based on Geography:
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
In the year 2022, the autologous treatment category led the market with a revenue share of 94.64%. This category is likewise expected to expand quicker throughout the predicted period. The increased acceptance of multiple CAR-T treatments due to their favourable outcomes for the treatment of various types of malignancies and genetic abnormalities is credited to the segment’s rise.
Some of these medicines have been authorised by the FDA, and their widespread use is now underway. For example, in February 2022, the FDA approved ciltacabtagene autoleucel (Carvykti) for adult patients with multiple myeloma. This medication is used to treat illnesses that are unresponsive to refractory treatments or that have relapsed following treatment.
From 2023 to 2030, the global cell therapy business is expected to see significant expansion in the allogenic cell therapy category. The rapid rise can be due to its widespread use in developing innovative therapy regimens. There are now 542 active allogenic CAR-T compounds in the worldwide pipeline, with many of them showing promising results. Adaptimmune Ltd., for example, partners with Genentech on the usefulness of allogeneic treatments obtained from iPSCs to generate T-cells with better proliferation ability than mature T-cells.
In 2022, the oncology category led the overall market, accounting for 38.23% of total revenue. CAR T-cells targeting CD19 are said to treat patients with Acute lymphocytic leukaemia (ALL) with high rates of full and long-term remission. Furthermore, increased FDA clearance for innovative medicines is projected to spur development in the cell therapy business.
For example, the FDA in the United States authorised the use of brexucabtagene autoleucel (Tecartus), a CAR-T therapy, in October 2021 for people with B-cell precursor ALL who have not responded to prior treatment (refractory) or whose illness has reappeared after treatment. Brexucabtagene was approved as the first CAR-T therapy for people with ALL.
The market for musculoskeletal diseases is predicted to increase significantly in the future years. Extensive research is being conducted to develop technologies that aid in the regeneration or repair of injured musculoskeletal tissues. Various research organisations investigate clinically relevant cell types used in treatments to treat musculoskeletal tissue degeneration and use engineered or native skeletal progenitor cells to directly trigger tissue repair and rejuvenate musculoskeletal tissues.
In 2022, North America held the greatest cell therapy market share of 65.15%. This is due to coordinated research endeavors by regional research institutes and pharmaceutical behemoths. Numerous partnerships are resulting in new breakthroughs in the region. Immatics, for example, worked with Bristol Myers Squibb in June 2022 to create Gamma Delta Allogeneic Cell Therapy Programs. Immatics and Bristol Myers will collaborate to develop two programs owned by Bristol Myers Squibb, with each business having the ability to develop up to four more programs.
Due to rising demand for cell therapy in the area, Asia Pacific is expected to have the quickest CAGR of 12.33% throughout the projected period. Certain factors, such as increased knowledge of innovative medicines, increased investment, and anticipated favorable government regulations, are predicted to boost market expansion throughout the forecast period. Tessa Therapeutics Ltd., for example, obtained USD 126 million in series investment in June 2022 to catalyze the development of next-generation cancer therapies.
- This report illustrates the most vital attributes of the Cell Therapy Technologies Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Cell Therapy Technologies Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Cell Therapy Technologies Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Cell Therapy Technologies Market.
List of Tables
TABLE 1. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 2. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ALLOGENEIC THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR AUTOLOGOUS THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 5. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR CARDIOVASCULAR DISEASE (CVD), BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR MUSCULOSKELETAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR DERMATOLOGY,2021-2030 (USD BILLION)
TABLE 9. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 11. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 14. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 15. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 16. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 17. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 18. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 19. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 20. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 21. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 22. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 23. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 24. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 25. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 26. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 27. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 28. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 29. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 30. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 31. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 32. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 33. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 34. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 35. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 36. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 37. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 38. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 39. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 40. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 41. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 42. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 43. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 44. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 45. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 46. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 47. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 48. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 49. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 50. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 51. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 52. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 53. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 54. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 55. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 56. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 57. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 58. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 59. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 60. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 61. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 62. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 63. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 64. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 65. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 66. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 67. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 68. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 69. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 70. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 71. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 72. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 73. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 74. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 75. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 76. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 77. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 78. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 79. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 80. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 81. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 82. NOVARTIS AG: FINANCIALS
TABLE 83. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 84. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 85. GILEAD SCIENCES, INC.: FINANCIALS
TABLE 86. GILEAD SCIENCES, INC.: PRODUCTS & SERVICES
TABLE 87. GILEAD SCIENCES, INC.: RECENT DEVELOPMENTS
TABLE 88. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 89. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 90. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 91. JOHNSON & JOHNSON SERVICES, INC: FINANCIALS
TABLE 92. JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES
TABLE 93. JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS
TABLE 94. JCR PHARMACEUTICALS CO., LTD.: FINANCIALS
TABLE 95. JCR PHARMACEUTICALS CO., LTD.: PRODUCTS & SERVICES
TABLE 96. JCR PHARMACEUTICALS CO., LTD.: RECENT DEVELOPMENTS
TABLE 97. TEGO SCIENCE: FINANCIALS
TABLE 98. TEGO SCIENCE: PRODUCTS & SERVICES
TABLE 99. TEGO SCIENCE: RECENT DEVELOPMENTS
TABLE 100. ATARA BIOTHERAPEUTICS: FINANCIALS
TABLE 101. ATARA BIOTHERAPEUTICS: PRODUCTS & SERVICES
TABLE 102. ATARA BIOTHERAPEUTICS: DEVELOPMENTS
TABLE 103. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS
TABLE 104. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES
TABLE 105. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS
TABLE 106. BLUEBIRD BIO, INC.: FINANCIALS
TABLE 107. BLUEBIRD BIO, INC.: PRODUCTS & SERVICES
TABLE 108. BLUEBIRD BIO, INC.: RECENT DEVELOPMENTS
TABLE 109. DENDREON CORP.: FINANCIALS
TABLE 110. DENDREON CORP.: PRODUCTS & SERVICES
TABLE 111. DENDREON CORP.: RECENT DEVELOPMENTS
